Next Generation Antibody Therapeutics Market Research Report from 2023 forecast to 2029, by Manufacturers, Regions, Type and Application

The global Next Generation Antibody Therapeutics market size was valued at USD 9878.9 million in 2022 and is forecast to a readjusted size of USD 36620 million by 2029 with a CAGR of 20.6% during review period.

Building on the huge success of monoclonal antibody therapeutics, the next generation of antibody-based products such as Antibody Drug Conjugate (ADC) and Bispecific Antibody (BsAb) is now opening up new opportunities.

Global key players of next generation antibody therapeutics include Roche, Seagen, Amgen, Pfizer, Takeda, etc. The top two players hold a share over 70%. North America is the largest market, has a share about 65%, followed by Europe and Asia-Pacific, with share 16% and 15%, separately. In terms of product type, Antibody Drug Conjugate (ADC) is the largest segment, occupied for a share of 60%, and in terms of application, Cancer has a share about 66 percent.

This report is a detailed and comprehensive analysis for global Next Generation Antibody Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Next Generation Antibody Therapeutics market size and forecasts, in consumption value ($ Million), 2018-2029
Global Next Generation Antibody Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Next Generation Antibody Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Next Generation Antibody Therapeutics market shares of main players, in revenue ($ Million), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Next Generation Antibody Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace

This report profiles key players in the global Next Generation Antibody Therapeutics market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

   Roche
   Amgen
   Pfizer
   Takeda
   Daiichi Sankyo
   Seagen
   Astellas
   Immunomedics
   GSK
   Immunocore
   ADC Therapeutics

   Antibody Drug Conjugate (ADC)
   Bispecific Antibody (BsAb)

   Cancer
   Haemophilia
   Other Non-Cancer Diseases

   North America (United States, Canada, and Mexico)
   Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
   Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
   South America (Brazil, Argentina and Rest of South America)
   Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

What are the strengths of the Next Generation Antibody Therapeutics Market in 2025?

The next generation antibody therapeutics market is poised for significant growth due to advancements in antibody engineering, enabling more targeted and personalized treatments. Additionally, improved efficacy and reduced side effects are expected to enhance patient outcomes, making these therapies highly attractive in oncology, autoimmune disorders, and infectious diseases.

What are the weaknesses of the Next Generation Antibody Therapeutics Market in 2025?

A key weakness is the high cost associated with the development and production of next-generation antibody therapeutics, which could limit their accessibility. Moreover, the complexity of manufacturing and potential immunogenicity risks may pose challenges for widespread adoption.

What are the opportunities in the Next Generation Antibody Therapeutics Market in 2025?

There are significant opportunities in expanding antibody-based treatments for rare and complex diseases, such as neurodegenerative conditions and genetic disorders. Moreover, collaborations between biotech companies and research institutions will accelerate the discovery of novel antibody candidates, driving market growth.

What are the threats to the Next Generation Antibody Therapeutics Market in 2025?

The market faces threats from emerging competition in the form of alternative therapies, such as gene editing and small molecule drugs. Additionally, regulatory hurdles and the lengthy approval processes for new treatments could delay market entry and affect the commercialization of new therapies.

What are the political factors affecting the Next Generation Antibody Therapeutics Market in 2025?

Government policies regarding healthcare funding, drug approvals, and regulatory pathways will significantly impact the market. Political stability and healthcare reforms, such as those in the U.S. and Europe, could facilitate faster approval processes and increased investments in biotech research.

What are the economic factors affecting the Next Generation Antibody Therapeutics Market in 2025?

Economic conditions, such as healthcare spending and the affordability of cutting-edge treatments, will influence market growth. High treatment costs and reimbursement issues could limit patient access, especially in emerging economies. On the other hand, increasing investments in biotechnology and healthcare infrastructure could provide significant economic opportunities.

What are the social factors affecting the Next Generation Antibody Therapeutics Market in 2025?

Growing patient awareness and demand for personalized medicine are driving the market. Social acceptance of new, advanced treatments and changing attitudes towards biotech solutions will impact adoption rates. However, disparities in healthcare access across different regions may create challenges in achieving widespread usage.

What are the technological factors affecting the Next Generation Antibody Therapeutics Market in 2025?

Advancements in antibody engineering, including bispecific antibodies, antibody-drug conjugates, and monoclonal antibody optimization, will continue to drive innovation in the market. The rise of AI and machine learning in drug discovery and development is expected to accelerate the identification of new therapeutic targets, fostering technological progress.

What are the environmental factors affecting the Next Generation Antibody Therapeutics Market in 2025?

Environmental concerns related to the production processes, such as waste management and sustainability in biotech manufacturing, are becoming increasingly important. The market may face pressure to adopt greener, more sustainable practices to reduce its carbon footprint and meet regulatory standards.

What are the legal factors affecting the Next Generation Antibody Therapeutics Market in 2025?

Intellectual property protection, patent laws, and regulatory approval processes will play a crucial role in shaping the market. Strong patent portfolios are essential for the protection of new antibody therapeutics, while changes in healthcare laws and policies could either ease or complicate market entry and commercialization.

Who are the suppliers in the Next Generation Antibody Therapeutics Market 2025?

Suppliers include biotech and pharmaceutical companies, research institutions, contract research organizations (CROs), and raw material providers for the production of antibodies, including cell lines and reagents. These entities are key in providing the resources required for the development and manufacturing of next-generation antibody therapeutics.

What are the inputs in the Next Generation Antibody Therapeutics Market 2025?

The inputs consist of advanced biotechnology research, monoclonal antibodies, genetic data, state-of-the-art lab equipment, and skilled researchers. Furthermore, regulatory frameworks and financial investments in R&D play a crucial role in the progression of these therapies.

What is the process in the Next Generation Antibody Therapeutics Market 2025?

The process involves identifying therapeutic targets, designing and engineering next-generation antibodies, conducting preclinical trials, and navigating regulatory approval pathways. It also includes manufacturing, scaling up production, and ensuring the quality control of these biologics.

Who are the customers in the Next Generation Antibody Therapeutics Market 2025?

Customers primarily include healthcare providers such as hospitals, clinics, and specialty treatment centers, as well as patients requiring cutting-edge therapies for cancer, autoimmune diseases, and other complex conditions. Pharmaceutical distributors and insurers also play a role in the market's customer landscape.

What are the outputs in the Next Generation Antibody Therapeutics Market 2025?

The outputs are next-generation antibody therapeutics that target diseases with high unmet medical needs. These therapeutics include monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates, designed to offer improved efficacy, precision, and safety for patients.

What is the threat of new entrants in the Next Generation Antibody Therapeutics Market 2025?

The threat of new entrants is relatively moderate. While the market holds significant potential, high R&D costs, complex regulatory approval processes, and the need for advanced technological expertise act as barriers to entry. Established pharmaceutical and biotech companies dominate, making it challenging for new players to enter without substantial resources.

What is the bargaining power of suppliers in the Next Generation Antibody Therapeutics Market 2025?

The bargaining power of suppliers is moderate to high. Suppliers of raw materials, specialized reagents, and biotechnological equipment are essential to the production process, and their influence can be significant, especially given the complexity of antibody development. However, the increasing number of suppliers in the biotech sector is creating some balance.

What is the bargaining power of buyers in the Next Generation Antibody Therapeutics Market 2025?

The bargaining power of buyers, especially large healthcare providers and pharmaceutical distributors, is moderate. As the number of antibody therapeutics grows, there is more choice for treatment options, but these therapies remain highly specialized, so buyers are limited in their negotiating leverage, particularly with innovative, cutting-edge treatments.

What is the threat of substitute products in the Next Generation Antibody Therapeutics Market 2025?

The threat of substitutes is moderate. While alternatives like gene therapy, small molecule drugs, and other biologics exist, next-generation antibody therapeutics provide unique advantages, particularly in targeting specific diseases with precision. However, as other treatments, such as immunotherapies and cell therapies, advance, they may pose competition.

What is the intensity of competitive rivalry in the Next Generation Antibody Therapeutics Market 2025?

The intensity of competitive rivalry is high. Numerous large pharmaceutical companies and biotech firms are aggressively investing in next-generation antibody therapies, leading to significant competition. Companies are focused on developing innovative treatments, improving efficacy, and reducing side effects, which fuels rivalry in this rapidly evolving market.

What are the key raw materials required in the Next Generation Antibody Therapeutics Market 2025?

The key raw materials include high-quality cell lines, biologically active proteins, growth factors, reagents for antibody production, and specialized culture media. These are essential for the creation and optimization of monoclonal and bispecific antibodies.

What are the main suppliers in the Next Generation Antibody Therapeutics Market 2025?

Main suppliers include biotechnology companies, contract manufacturing organizations (CMOs), suppliers of biologic reagents, and specialized equipment manufacturers. These entities provide the necessary tools, materials, and infrastructure for research and production of next-generation antibody therapeutics.

What are the technological requirements in the Next Generation Antibody Therapeutics Market 2025?

The market requires advanced biotechnological platforms such as recombinant DNA technology, protein engineering, and monoclonal antibody development. Cutting-edge tools like CRISPR and AI-based drug discovery are also pivotal in enhancing antibody design, optimization, and production.

What are the regulatory challenges in the Next Generation Antibody Therapeutics Market 2025?

Regulatory challenges include navigating complex approval processes for biologics, ensuring the safety and efficacy of new antibody therapies, and meeting stringent quality control standards. These challenges can delay product development and increase costs, impacting the supply chain for upstream materials.

What is the impact of research and development on the upstream market for Next Generation Antibody Therapeutics?

R&D plays a critical role in upstream activities by driving innovation in antibody design and production techniques. The development of new, more efficient manufacturing processes and the discovery of novel therapeutic targets significantly influence the sourcing of raw materials, shaping supply chain dynamics.

What are the key processes involved in the midstream of the Next Generation Antibody Therapeutics Market 2025?

The midstream processes include the development and manufacturing of the next-generation antibody therapeutics, including cell line optimization, large-scale production, purification, and formulation. This stage also involves scaling up production to meet market demand while maintaining high standards of quality control.

What are the main players in the midstream of the Next Generation Antibody Therapeutics Market 2025?

Main players in the midstream include contract manufacturing organizations (CMOs), specialized biotech firms, and facilities responsible for large-scale production and distribution. These entities are responsible for transforming lab-scale antibody candidates into commercial-ready therapies.

What are the technological requirements in the midstream of the Next Generation Antibody Therapeutics Market 2025?

Technological requirements include advanced bioreactor systems, purification techniques like protein A chromatography, and automation for high-throughput screening and production. Innovations in continuous manufacturing and automation are enhancing efficiency and reducing costs in this stage.

What are the quality control and regulatory aspects in the midstream of the Next Generation Antibody Therapeutics Market 2025?

Quality control is critical in ensuring that the produced antibodies meet rigorous safety, efficacy, and purity standards. Regulatory compliance, including adherence to Good Manufacturing Practices (GMP) and regular inspections by regulatory bodies like the FDA and EMA, ensures the safety and reliability of the therapeutic products.

What are the distribution and logistics challenges in the midstream of the Next Generation Antibody Therapeutics Market 2025?

Distribution and logistics challenges include ensuring the stable transport of temperature-sensitive biologics and managing supply chain complexities. Coordinating with healthcare providers, pharmacies, and distributors to maintain timely availability while ensuring proper storage conditions is critical for market success.

What are the key activities involved in the downstream of the Next Generation Antibody Therapeutics Market 2025?

The downstream activities include the distribution, marketing, and commercialization of next-generation antibody therapeutics. This stage also involves post-market surveillance, patient support programs, and ensuring the availability of the therapy to healthcare providers and patients through effective distribution networks.

What are the main players in the downstream of the Next Generation Antibody Therapeutics Market 2025?

Main players in the downstream include pharmaceutical companies, healthcare providers, hospitals, specialty pharmacies, and distributors. These entities manage the delivery, sale, and post-market management of antibody therapies, ensuring they reach the right patients at the right time.

What are the challenges in the downstream of the Next Generation Antibody Therapeutics Market 2025?

Challenges include managing the high costs of therapy, which may limit access for some patients, and ensuring reimbursement from insurance companies. Additionally, the logistics of cold chain management for biologics and maintaining supply consistency across global markets remain complex issues.

What role does marketing play in the downstream of the Next Generation Antibody Therapeutics Market 2025?

Marketing plays a critical role in educating healthcare providers and patients about the benefits and potential of next-generation antibody therapeutics. Effective marketing strategies involve building awareness, addressing unmet medical needs, and promoting the unique value proposition of these therapies to different stakeholders.

What is the impact of regulatory approval and pricing on the downstream of the Next Generation Antibody Therapeutics Market 2025?

Regulatory approval and pricing directly impact market access and product availability. Once approved, pricing strategies must balance cost-effectiveness for healthcare systems while ensuring profitability for manufacturers. In addition, regulatory policies regarding reimbursement and pricing can either facilitate or hinder the widespread adoption of these therapies.

Chapter 1, to describe Next Generation Antibody Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Next Generation Antibody Therapeutics, with revenue, gross margin and global market share of Next Generation Antibody Therapeutics from 2018 to 2023.
Chapter 3, the Next Generation Antibody Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Next Generation Antibody Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Next Generation Antibody Therapeutics.
Chapter 13, to describe Next Generation Antibody Therapeutics research findings and conclusion.

1 Market Overview

   1.1 Product Overview and Scope of Next Generation Antibody Therapeutics
   1.2 Market Estimation Caveats and Base Year
   1.3 Classification of Next Generation Antibody Therapeutics by Type
       1.3.1 Overview: Global Next Generation Antibody Therapeutics Market Size by Type: 2018 Versus 2022 Versus 2029
       1.3.2 Global Next Generation Antibody Therapeutics Consumption Value Market Share by Type in 2022
       1.3.3 Antibody Drug Conjugate (ADC)
       1.3.4 Bispecific Antibody (BsAb)
   1.4 Global Next Generation Antibody Therapeutics Market by Application
       1.4.1 Overview: Global Next Generation Antibody Therapeutics Market Size by Application: 2018 Versus 2022 Versus 2029
       1.4.2 Cancer
       1.4.3 Haemophilia
       1.4.4 Other Non-Cancer Diseases
   1.5 Global Next Generation Antibody Therapeutics Market Size & Forecast
   1.6 Global Next Generation Antibody Therapeutics Market Size and Forecast by Region
       1.6.1 Global Next Generation Antibody Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
       1.6.2 Global Next Generation Antibody Therapeutics Market Size by Region, (2018-2029)
       1.6.3 North America Next Generation Antibody Therapeutics Market Size and Prospect (2018-2029)
       1.6.4 Europe Next Generation Antibody Therapeutics Market Size and Prospect (2018-2029)
       1.6.5 Asia-Pacific Next Generation Antibody Therapeutics Market Size and Prospect (2018-2029)
       1.6.6 South America Next Generation Antibody Therapeutics Market Size and Prospect (2018-2029)
       1.6.7 Middle East and Africa Next Generation Antibody Therapeutics Market Size and Prospect (2018-2029)

2 Company Profiles

   2.1 Roche
       2.1.1 Roche Details
       2.1.2 Roche Major Business
       2.1.3 Roche Next Generation Antibody Therapeutics Product and Solutions
       2.1.4 Roche Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
       2.1.5 Roche Recent Developments and Future Plans
   2.2 Amgen
       2.2.1 Amgen Details
       2.2.2 Amgen Major Business
       2.2.3 Amgen Next Generation Antibody Therapeutics Product and Solutions
       2.2.4 Amgen Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
       2.2.5 Amgen Recent Developments and Future Plans
   2.3 Pfizer
       2.3.1 Pfizer Details
       2.3.2 Pfizer Major Business
       2.3.3 Pfizer Next Generation Antibody Therapeutics Product and Solutions
       2.3.4 Pfizer Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
       2.3.5 Pfizer Recent Developments and Future Plans
   2.4 Takeda
       2.4.1 Takeda Details
       2.4.2 Takeda Major Business
       2.4.3 Takeda Next Generation Antibody Therapeutics Product and Solutions
       2.4.4 Takeda Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
       2.4.5 Takeda Recent Developments and Future Plans
   2.5 Daiichi Sankyo
       2.5.1 Daiichi Sankyo Details
       2.5.2 Daiichi Sankyo Major Business
       2.5.3 Daiichi Sankyo Next Generation Antibody Therapeutics Product and Solutions
       2.5.4 Daiichi Sankyo Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
       2.5.5 Daiichi Sankyo Recent Developments and Future Plans
   2.6 Seagen
       2.6.1 Seagen Details
       2.6.2 Seagen Major Business
       2.6.3 Seagen Next Generation Antibody Therapeutics Product and Solutions
       2.6.4 Seagen Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
       2.6.5 Seagen Recent Developments and Future Plans
   2.7 Astellas
       2.7.1 Astellas Details
       2.7.2 Astellas Major Business
       2.7.3 Astellas Next Generation Antibody Therapeutics Product and Solutions
       2.7.4 Astellas Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
       2.7.5 Astellas Recent Developments and Future Plans
   2.8 Immunomedics
       2.8.1 Immunomedics Details
       2.8.2 Immunomedics Major Business
       2.8.3 Immunomedics Next Generation Antibody Therapeutics Product and Solutions
       2.8.4 Immunomedics Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
       2.8.5 Immunomedics Recent Developments and Future Plans
   2.9 GSK
       2.9.1 GSK Details
       2.9.2 GSK Major Business
       2.9.3 GSK Next Generation Antibody Therapeutics Product and Solutions
       2.9.4 GSK Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
       2.9.5 GSK Recent Developments and Future Plans
   2.10 Immunocore 
       2.10.1 Immunocore Details
       2.10.2 Immunocore Major Business
       2.10.3 Immunocore Next Generation Antibody Therapeutics Product and Solutions
       2.10.4 Immunocore Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
       2.10.5 Immunocore Recent Developments and Future Plans
   2.11 ADC Therapeutics
       2.11.1 ADC Therapeutics Details
       2.11.2 ADC Therapeutics Major Business
       2.11.3 ADC Therapeutics Next Generation Antibody Therapeutics Product and Solutions
       2.11.4 ADC Therapeutics Next Generation Antibody Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
       2.11.5 ADC Therapeutics Recent Developments and Future Plans

3 Market Competition, by Players

   3.1 Global Next Generation Antibody Therapeutics Revenue and Share by Players (2018-2023)
   3.2 Market Share Analysis (2022)
       3.2.1 Market Share of Next Generation Antibody Therapeutics by Company Revenue
       3.2.2 Top 3 Next Generation Antibody Therapeutics Players Market Share in 2022
       3.2.3 Top 6 Next Generation Antibody Therapeutics Players Market Share in 2022
   3.3 Next Generation Antibody Therapeutics Market: Overall Company Footprint Analysis
       3.3.1 Next Generation Antibody Therapeutics Market: Region Footprint
       3.3.2 Next Generation Antibody Therapeutics Market: Company Product Type Footprint
       3.3.3 Next Generation Antibody Therapeutics Market: Company Product Application Footprint
   3.4 New Market Entrants and Barriers to Market Entry
   3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

   4.1 Global Next Generation Antibody Therapeutics Consumption Value and Market Share by Type (2018-2023)
   4.2 Global Next Generation Antibody Therapeutics Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

   5.1 Global Next Generation Antibody Therapeutics Consumption Value Market Share by Application (2018-2023)
   5.2 Global Next Generation Antibody Therapeutics Market Forecast by Application (2024-2029)

6 North America

   6.1 North America Next Generation Antibody Therapeutics Consumption Value by Type (2018-2029)
   6.2 North America Next Generation Antibody Therapeutics Consumption Value by Application (2018-2029)
   6.3 North America Next Generation Antibody Therapeutics Market Size by Country
       6.3.1 North America Next Generation Antibody Therapeutics Consumption Value by Country (2018-2029)
       6.3.2 United States Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
       6.3.3 Canada Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
       6.3.4 Mexico Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)

7 Europe

   7.1 Europe Next Generation Antibody Therapeutics Consumption Value by Type (2018-2029)
   7.2 Europe Next Generation Antibody Therapeutics Consumption Value by Application (2018-2029)
   7.3 Europe Next Generation Antibody Therapeutics Market Size by Country
       7.3.1 Europe Next Generation Antibody Therapeutics Consumption Value by Country (2018-2029)
       7.3.2 Germany Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
       7.3.3 France Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
       7.3.4 United Kingdom Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
       7.3.5 Russia Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
       7.3.6 Italy Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)

8 Asia-Pacific

   8.1 Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Type (2018-2029)
   8.2 Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Application (2018-2029)
   8.3 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region
       8.3.1 Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Region (2018-2029)
       8.3.2 China Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
       8.3.3 Japan Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
       8.3.4 South Korea Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
       8.3.5 India Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
       8.3.6 Southeast Asia Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
       8.3.7 Australia Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)

9 South America

   9.1 South America Next Generation Antibody Therapeutics Consumption Value by Type (2018-2029)
   9.2 South America Next Generation Antibody Therapeutics Consumption Value by Application (2018-2029)
   9.3 South America Next Generation Antibody Therapeutics Market Size by Country
       9.3.1 South America Next Generation Antibody Therapeutics Consumption Value by Country (2018-2029)
       9.3.2 Brazil Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
       9.3.3 Argentina Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)

10 Middle East & Africa

   10.1 Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Type (2018-2029)
   10.2 Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Application (2018-2029)
   10.3 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country
       10.3.1 Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Country (2018-2029)
       10.3.2 Turkey Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
       10.3.3 Saudi Arabia Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)
       10.3.4 UAE Next Generation Antibody Therapeutics Market Size and Forecast (2018-2029)

11 Market Dynamics

   11.1 Next Generation Antibody Therapeutics Market Drivers
   11.2 Next Generation Antibody Therapeutics Market Restraints
   11.3 Next Generation Antibody Therapeutics Trends Analysis
   11.4 Porters Five Forces Analysis
       11.4.1 Threat of New Entrants
       11.4.2 Bargaining Power of Suppliers
       11.4.3 Bargaining Power of Buyers
       11.4.4 Threat of Substitutes
       11.4.5 Competitive Rivalry
   11.5 Influence of COVID-19 and Russia-Ukraine War
       11.5.1 Influence of COVID-19
       11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

   12.1 Next Generation Antibody Therapeutics Industry Chain
   12.2 Next Generation Antibody Therapeutics Upstream Analysis
   12.3 Next Generation Antibody Therapeutics Midstream Analysis
   12.4 Next Generation Antibody Therapeutics Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

   14.1 Methodology
   14.2 Research Process and Data Source
   14.3 Disclaimer

List of Tables

   Table 1. Global Next Generation Antibody Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Table 2. Global Next Generation Antibody Therapeutics Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
   Table 3. Global Next Generation Antibody Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
   Table 4. Global Next Generation Antibody Therapeutics Consumption Value by Region (2024-2029) & (USD Million)
   Table 5. Roche Company Information, Head Office, and Major Competitors
   Table 6. Roche Major Business
   Table 7. Roche Next Generation Antibody Therapeutics Product and Solutions
   Table 8. Roche Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 9. Roche Recent Developments and Future Plans
   Table 10. Amgen Company Information, Head Office, and Major Competitors
   Table 11. Amgen Major Business
   Table 12. Amgen Next Generation Antibody Therapeutics Product and Solutions
   Table 13. Amgen Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 14. Amgen Recent Developments and Future Plans
   Table 15. Pfizer Company Information, Head Office, and Major Competitors
   Table 16. Pfizer Major Business
   Table 17. Pfizer Next Generation Antibody Therapeutics Product and Solutions
   Table 18. Pfizer Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 19. Pfizer Recent Developments and Future Plans
   Table 20. Takeda Company Information, Head Office, and Major Competitors
   Table 21. Takeda Major Business
   Table 22. Takeda Next Generation Antibody Therapeutics Product and Solutions
   Table 23. Takeda Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 24. Takeda Recent Developments and Future Plans
   Table 25. Daiichi Sankyo Company Information, Head Office, and Major Competitors
   Table 26. Daiichi Sankyo Major Business
   Table 27. Daiichi Sankyo Next Generation Antibody Therapeutics Product and Solutions
   Table 28. Daiichi Sankyo Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 29. Daiichi Sankyo Recent Developments and Future Plans
   Table 30. Seagen Company Information, Head Office, and Major Competitors
   Table 31. Seagen Major Business
   Table 32. Seagen Next Generation Antibody Therapeutics Product and Solutions
   Table 33. Seagen Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 34. Seagen Recent Developments and Future Plans
   Table 35. Astellas Company Information, Head Office, and Major Competitors
   Table 36. Astellas Major Business
   Table 37. Astellas Next Generation Antibody Therapeutics Product and Solutions
   Table 38. Astellas Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 39. Astellas Recent Developments and Future Plans
   Table 40. Immunomedics Company Information, Head Office, and Major Competitors
   Table 41. Immunomedics Major Business
   Table 42. Immunomedics Next Generation Antibody Therapeutics Product and Solutions
   Table 43. Immunomedics Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 44. Immunomedics Recent Developments and Future Plans
   Table 45. GSK Company Information, Head Office, and Major Competitors
   Table 46. GSK Major Business
   Table 47. GSK Next Generation Antibody Therapeutics Product and Solutions
   Table 48. GSK Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 49. GSK Recent Developments and Future Plans
   Table 50. Immunocore Company Information, Head Office, and Major Competitors
   Table 51. Immunocore Major Business
   Table 52. Immunocore Next Generation Antibody Therapeutics Product and Solutions
   Table 53. Immunocore Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 54. Immunocore Recent Developments and Future Plans
   Table 55. ADC Therapeutics Company Information, Head Office, and Major Competitors
   Table 56. ADC Therapeutics Major Business
   Table 57. ADC Therapeutics Next Generation Antibody Therapeutics Product and Solutions
   Table 58. ADC Therapeutics Next Generation Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 59. ADC Therapeutics Recent Developments and Future Plans
   Table 60. Global Next Generation Antibody Therapeutics Revenue (USD Million) by Players (2018-2023)
   Table 61. Global Next Generation Antibody Therapeutics Revenue Share by Players (2018-2023)
   Table 62. Breakdown of Next Generation Antibody Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3)
   Table 63. Market Position of Players in Next Generation Antibody Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
   Table 64. Head Office of Key Next Generation Antibody Therapeutics Players
   Table 65. Next Generation Antibody Therapeutics Market: Company Product Type Footprint
   Table 66. Next Generation Antibody Therapeutics Market: Company Product Application Footprint
   Table 67. Next Generation Antibody Therapeutics New Market Entrants and Barriers to Market Entry
   Table 68. Next Generation Antibody Therapeutics Mergers, Acquisition, Agreements, and Collaborations
   Table 69. Global Next Generation Antibody Therapeutics Consumption Value (USD Million) by Type (2018-2023)
   Table 70. Global Next Generation Antibody Therapeutics Consumption Value Share by Type (2018-2023)
   Table 71. Global Next Generation Antibody Therapeutics Consumption Value Forecast by Type (2024-2029)
   Table 72. Global Next Generation Antibody Therapeutics Consumption Value by Application (2018-2023)
   Table 73. Global Next Generation Antibody Therapeutics Consumption Value Forecast by Application (2024-2029)
   Table 74. North America Next Generation Antibody Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
   Table 75. North America Next Generation Antibody Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
   Table 76. North America Next Generation Antibody Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
   Table 77. North America Next Generation Antibody Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
   Table 78. North America Next Generation Antibody Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
   Table 79. North America Next Generation Antibody Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
   Table 80. Europe Next Generation Antibody Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
   Table 81. Europe Next Generation Antibody Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
   Table 82. Europe Next Generation Antibody Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
   Table 83. Europe Next Generation Antibody Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
   Table 84. Europe Next Generation Antibody Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
   Table 85. Europe Next Generation Antibody Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
   Table 86. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
   Table 87. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
   Table 88. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
   Table 89. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
   Table 90. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
   Table 91. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value by Region (2024-2029) & (USD Million)
   Table 92. South America Next Generation Antibody Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
   Table 93. South America Next Generation Antibody Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
   Table 94. South America Next Generation Antibody Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
   Table 95. South America Next Generation Antibody Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
   Table 96. South America Next Generation Antibody Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
   Table 97. South America Next Generation Antibody Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
   Table 98. Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
   Table 99. Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
   Table 100. Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
   Table 101. Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
   Table 102. Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
   Table 103. Middle East & Africa Next Generation Antibody Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
   Table 104. Next Generation Antibody Therapeutics Raw Material
   Table 105. Key Suppliers of Next Generation Antibody Therapeutics Raw Materials

List of Figures

   Figure 1. Next Generation Antibody Therapeutics Picture
   Figure 2. Global Next Generation Antibody Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Figure 3. Global Next Generation Antibody Therapeutics Consumption Value Market Share by Type in 2022
   Figure 4. Antibody Drug Conjugate (ADC)
   Figure 5. Bispecific Antibody (BsAb)
   Figure 6. Global Next Generation Antibody Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Figure 7. Next Generation Antibody Therapeutics Consumption Value Market Share by Application in 2022
   Figure 8. Cancer Picture
   Figure 9. Haemophilia Picture
   Figure 10. Other Non-Cancer Diseases Picture
   Figure 11. Global Next Generation Antibody Therapeutics Consumption Value, (USD Million): 2018 & 2022 & 2029
   Figure 12. Global Next Generation Antibody Therapeutics Consumption Value and Forecast (2018-2029) & (USD Million)
   Figure 13. Global Market Next Generation Antibody Therapeutics Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
   Figure 14. Global Next Generation Antibody Therapeutics Consumption Value Market Share by Region (2018-2029)
   Figure 15. Global Next Generation Antibody Therapeutics Consumption Value Market Share by Region in 2022
   Figure 16. North America Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
   Figure 17. Europe Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
   Figure 18. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
   Figure 19. South America Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
   Figure 20. Middle East and Africa Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
   Figure 21. Global Next Generation Antibody Therapeutics Revenue Share by Players in 2022
   Figure 22. Next Generation Antibody Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
   Figure 23. Global Top 3 Players Next Generation Antibody Therapeutics Market Share in 2022
   Figure 24. Global Top 6 Players Next Generation Antibody Therapeutics Market Share in 2022
   Figure 25. Global Next Generation Antibody Therapeutics Consumption Value Share by Type (2018-2023)
   Figure 26. Global Next Generation Antibody Therapeutics Market Share Forecast by Type (2024-2029)
   Figure 27. Global Next Generation Antibody Therapeutics Consumption Value Share by Application (2018-2023)
   Figure 28. Global Next Generation Antibody Therapeutics Market Share Forecast by Application (2024-2029)
   Figure 29. North America Next Generation Antibody Therapeutics Consumption Value Market Share by Type (2018-2029)
   Figure 30. North America Next Generation Antibody Therapeutics Consumption Value Market Share by Application (2018-2029)
   Figure 31. North America Next Generation Antibody Therapeutics Consumption Value Market Share by Country (2018-2029)
   Figure 32. United States Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
   Figure 33. Canada Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
   Figure 34. Mexico Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
   Figure 35. Europe Next Generation Antibody Therapeutics Consumption Value Market Share by Type (2018-2029)
   Figure 36. Europe Next Generation Antibody Therapeutics Consumption Value Market Share by Application (2018-2029)
   Figure 37. Europe Next Generation Antibody Therapeutics Consumption Value Market Share by Country (2018-2029)
   Figure 38. Germany Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
   Figure 39. France Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
   Figure 40. United Kingdom Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
   Figure 41. Russia Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
   Figure 42. Italy Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
   Figure 43. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value Market Share by Type (2018-2029)
   Figure 44. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value Market Share by Application (2018-2029)
   Figure 45. Asia-Pacific Next Generation Antibody Therapeutics Consumption Value Market Share by Region (2018-2029)
   Figure 46. China Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
   Figure 47. Japan Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
   Figure 48. South Korea Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
   Figure 49. India Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
   Figure 50. Southeast Asia Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
   Figure 51. Australia Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
   Figure 52. South America Next Generation Antibody Therapeutics Consumption Value Market Share by Type (2018-2029)
   Figure 53. South America Next Generation Antibody Therapeutics Consumption Value Market Share by Application (2018-2029)
   Figure 54. South America Next Generation Antibody Therapeutics Consumption Value Market Share by Country (2018-2029)
   Figure 55. Brazil Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
   Figure 56. Argentina Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
   Figure 57. Middle East and Africa Next Generation Antibody Therapeutics Consumption Value Market Share by Type (2018-2029)
   Figure 58. Middle East and Africa Next Generation Antibody Therapeutics Consumption Value Market Share by Application (2018-2029)
   Figure 59. Middle East and Africa Next Generation Antibody Therapeutics Consumption Value Market Share by Country (2018-2029)
   Figure 60. Turkey Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
   Figure 61. Saudi Arabia Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
   Figure 62. UAE Next Generation Antibody Therapeutics Consumption Value (2018-2029) & (USD Million)
   Figure 63. Next Generation Antibody Therapeutics Market Drivers
   Figure 64. Next Generation Antibody Therapeutics Market Restraints
   Figure 65. Next Generation Antibody Therapeutics Market Trends
   Figure 66. Porters Five Forces Analysis
   Figure 67. Manufacturing Cost Structure Analysis of Next Generation Antibody Therapeutics in 2022
   Figure 68. Manufacturing Process Analysis of Next Generation Antibody Therapeutics
   Figure 69. Next Generation Antibody Therapeutics Industrial Chain
   Figure 70. Methodology
   Figure 71. Research Process and Data Source